Recombinant Alexa Fluor® 647 Anti-Cytokeratin 10 antibody [EP1607IHCY] (ab194231)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Alexa Fluor® 647 Rabbit monoclonal [EP1607IHCY] to Cytokeratin 10
- Suitable for: ICC/IF
- Reacts with: Human
- Conjugation: Alexa Fluor® 647. Ex: 652nm, Em: 668nm
Related conjugates and formulations
Product nameAlexa Fluor® 647 Anti-Cytokeratin 10 antibody [EP1607IHCY]
See all Cytokeratin 10 primary antibodies
DescriptionAlexa Fluor® 647 Rabbit monoclonal [EP1607IHCY] to Cytokeratin 10
ConjugationAlexa Fluor® 647. Ex: 652nm, Em: 668nm
Tested applicationsSuitable for: ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
- ICC/IF: A431 cells.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or firstname.lastname@example.org.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Concentration information loading...
PurityProtein A purified
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab194231 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Signal can be observed in cells fixed with MeOH or PFA.
Signal can be observed in cells fixed with MeOH or PFA.
Tissue specificitySeen in all suprabasal cell layers including stratum corneum.
Involvement in diseaseDefects in KRT10 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
Defects in KRT10 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months.
Sequence similaritiesBelongs to the intermediate filament family.
- Information by UniProt
- Entrez Gene: 3858 Human
- Entrez Gene: 16661 Mouse
- Entrez Gene: 450225 Rat
- Omim: 148080 Human
- SwissProt: P13645 Human
- SwissProt: P02535 Mouse
- SwissProt: Q6IFW6 Rat
- Unigene: 99936 Human
- BCIE antibody
- BIE antibody
- CK 10 antibody
Ab194231 staining Cytokeratin 10 in A431 cells. The cells were fixed with 100% methanol (5min), permeabilized in 0.1% Triton X-100 for 5 minutes and then blocked in 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated with ab194231 at a working dilution of 1 in 50 (shown in red) and ab7291 (Mouse monoclonal [DM1A] to alpha Tubulin) at 1µg/ml overnight at +4°C, followed by a further incubation at room temperature for 1h with an AlexaFluor®488 Goat anti-Mouse secondary (ab150117) at 2μg/ml (shown in green). Nuclear DNA was labelled in blue with DAPI.
This product also gave a positive signal in 4% formaldehyde (10min) fixed HeLa cells under the same testing conditions.
Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).
Datasheets and documents
ab194231 has been referenced in 2 publications.
- Wei F et al. Plasma endothelial cells-derived extracellular vesicles promote wound healing in diabetes through YAP and the PI3K/Akt/mTOR pathway. Aging (Albany NY) 12:12002-12018 (2020). PubMed: 32570219
- Luong D et al. Transition metal-doped cryogels as bioactive materials for wound healing applications. Mater Sci Eng C Mater Biol Appl 103:109759 (2019). PubMed: 31349449